Nanobiotix (NBTX) Competitors $20.51 +0.63 (+3.17%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$20.18 -0.33 (-1.58%) As of 10/3/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. TVTX, ETNB, AGIO, MESO, RXRX, IRON, OCUL, ANIP, ARQT, and ADPTShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Travere Therapeutics (TVTX), 89BIO (ETNB), Agios Pharmaceuticals (AGIO), Mesoblast (MESO), Recursion Pharmaceuticals (RXRX), Disc Medicine (IRON), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Arcutis Biotherapeutics (ARQT), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors Travere Therapeutics 89BIO Agios Pharmaceuticals Mesoblast Recursion Pharmaceuticals Disc Medicine Ocular Therapeutix ANI Pharmaceuticals Arcutis Biotherapeutics Adaptive Biotechnologies Nanobiotix (NASDAQ:NBTX) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment. Is NBTX or TVTX more profitable? Nanobiotix has a net margin of 0.00% compared to Travere Therapeutics' net margin of -50.64%. Nanobiotix's return on equity of 0.00% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A Travere Therapeutics -50.64%-717.68%-30.69% Which has better earnings & valuation, NBTX or TVTX? Nanobiotix has higher earnings, but lower revenue than Travere Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix$39.18M25.10-$73.73MN/AN/ATravere Therapeutics$233.18M9.42-$321.55M-$2.04-12.08 Do insiders and institutionals hold more shares of NBTX or TVTX? 38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 4.2% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to NBTX or TVTX? In the previous week, Nanobiotix had 13 more articles in the media than Travere Therapeutics. MarketBeat recorded 20 mentions for Nanobiotix and 7 mentions for Travere Therapeutics. Nanobiotix's average media sentiment score of 0.40 beat Travere Therapeutics' score of 0.40 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, NBTX or TVTX? Nanobiotix has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Do analysts rate NBTX or TVTX? Nanobiotix presently has a consensus target price of $11.00, suggesting a potential downside of 46.37%. Travere Therapeutics has a consensus target price of $34.20, suggesting a potential upside of 38.80%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Travere Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Travere Therapeutics 1 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryNanobiotix beats Travere Therapeutics on 8 of the 14 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$983.31M$2.61B$6.12B$10.58BDividend YieldN/A52.87%5.65%4.69%P/E RatioN/A24.2286.9626.71Price / Sales25.10724.90605.88130.98Price / CashN/A172.1237.9061.31Price / Book-13.585.3412.556.55Net Income-$73.73M$32.92M$3.31B$277.50M7 Day Performance26.29%3.90%4.28%2.42%1 Month Performance140.02%8.79%6.90%8.63%1 Year Performance295.18%-3.79%70.54%31.60% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix1.275 of 5 stars$20.51+3.2%$11.00-46.4%+295.2%$983.31M$39.18M0.00100News CoverageShort Interest ↓Analyst RevisionTVTXTravere Therapeutics2.402 of 5 stars$25.43+2.3%$34.20+34.5%+61.8%$2.22B$233.18M-12.47460Analyst UpgradeETNB89BIO3.1487 of 5 stars$14.87flat$25.81+73.6%+106.5%$2.21BN/A-4.1240Options VolumeHigh Trading VolumeAGIOAgios Pharmaceuticals4.4461 of 5 stars$38.19+1.3%$56.00+46.6%-2.0%$2.19B$36.50M3.47390Insider TradeMESOMesoblast2.0832 of 5 stars$16.85-0.9%$18.00+6.8%+70.3%$2.18B$17.20M0.0080News CoverageGap UpRXRXRecursion Pharmaceuticals2.2946 of 5 stars$4.98+1.4%$7.25+45.6%-10.1%$2.13B$58.84M-2.80400IRONDisc Medicine2.0187 of 5 stars$61.49+1.2%$98.30+59.9%+35.8%$2.11BN/A-13.7630OCULOcular Therapeutix4.0127 of 5 stars$12.20+0.8%$17.83+46.2%+16.0%$2.11B$63.72M-9.53230Trending NewsAnalyst ForecastAnalyst RevisionGap UpANIPANI Pharmaceuticals3.8752 of 5 stars$95.93-0.9%$93.00-3.1%+55.0%$2.10B$614.38M-124.58600ARQTArcutis Biotherapeutics1.3783 of 5 stars$17.38flat$19.80+13.9%+98.8%$2.08B$196.54M-23.17150News CoverageInsider TradeADPTAdaptive Biotechnologies3.1573 of 5 stars$13.94+4.3%$12.38-11.2%+160.5%$2.03B$178.96M-17.00790Analyst Forecast Related Companies and Tools Related Companies Travere Therapeutics Competitors 89BIO Competitors Agios Pharmaceuticals Competitors Mesoblast Competitors Recursion Pharmaceuticals Competitors Disc Medicine Competitors Ocular Therapeutix Competitors ANI Pharmaceuticals Competitors Arcutis Biotherapeutics Competitors Adaptive Biotechnologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
